{{Rsnum
|rsid=1256040
|Gene=ESR2
|Chromosome=14
|position=64271676
|Orientation=plus
|GMAF=0.4371
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ESR2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 19.7 | 45.9 | 34.4
| HCB | 25.0 | 50.0 | 25.0
| JPT | 16.3 | 55.8 | 27.9
| YRI | 14.5 | 54.8 | 30.6
| ASW | 0.0 | 0.0 | 0.0
| CHB | 25.0 | 50.0 | 25.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1256040
|Name_s=ESR2:rs1256040
|Gene_s=ESR2
|Feature=
|Evidence=PubMed ID:17579196
|Annotation=Haplotype tagging SNP.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161145072
}}

{{PMID|16551880}} Estrogen receptor beta polymorphism is associated with prostate cancer risk.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1256040
|overall_frequency_n=74
|overall_frequency_d=128
|overall_frequency=0.578125
|n_genomes=48
|n_genomes_annotated=0
|n_haplomes=64
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}